Literature DB >> 2939204

Distribution, retention, and phototoxicity of hematoporphyrin derivative in a rat glioma. Intraneoplastic versus intraperitoneal injection.

H Kostron, D A Bellnier, C W Lin, M R Swartz, R L Martuza.   

Abstract

The distribution, retention, and phototoxicity of the sensitizer hematoporphyrin derivative (HPD) were studied following intraperitoneal and direct intraneoplastic injections of the agent into subcutaneous or intracerebral gliosarcomas in rats. Forty-eight hours after intraperitoneal injection, the ratio of tritiated (3H) HPD in subcutaneous tumor: adjacent normal skin was about 1.4:1 and the ratio in tumor: normal brain was 3:1. In contrast, direct injection of 3H-HPD into subcutaneous tumors resulted in tumor: adjacent normal skin concentration ratios of approximately 44:1 and tumor: normal brain ratios of about 61:1. For rats bearing intracerebral gliosarcomas, intraperitoneal administration of 3H-HPD resulted in approximately 1.3-fold sensitization in tumor tissue relative to adjacent edematous brain. In contrast, after direct injection into intracerebral tumors, the tumor: adjacent edematous brain and tumor: skin 3H-HPD ratios were 3:1 and 32:1, respectively. In all cases, 3H-HPD was found in every portion of the tumor, even at a distance from the injection site. For the 3H-HPD doses used in this study, after direct injection both subcutaneous and intracerebral tumor tissue contained about three to four times more 3H-HPD than tumors in rats receiving intraperitoneal 3H-HPD. Both in vitro and in vivo clonogenic assays demonstrated that the photodynamic inactivation of the tumors was significantly greater after direct injection than after intraperitoneal injection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939204     DOI: 10.3171/jns.1986.64.5.0768

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Intratumor administration of the photosensitizer pc 4 affords photodynamic therapy efficacy and selectivity at short drug-light intervals.

Authors:  Thomas H Foster; Benjamin R Giesselman; Rui Hu; Malcolm E Kenney; Soumya Mitra
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

2.  Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo.

Authors:  W H Boehncke; K König; R Kaufmann; W Scheffold; O Prümmer; W Sterry
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

3.  Development and characterization of bio-derived polyhydroxyalkanoate nanoparticles as a delivery system for hydrophobic photodynamic therapy agents.

Authors:  Sasivimon Pramual; Apinya Assavanig; Magnus Bergkvist; Carl A Batt; Panya Sunintaboon; Kriengsak Lirdprapamongkol; Jisnuson Svasti; Nuttawee Niamsiri
Journal:  J Mater Sci Mater Med       Date:  2015-12-28       Impact factor: 3.896

4.  Increased efficacy of photodynamic therapy of R3230AC mammary adenocarcinoma by intratumoral injection of Photofrin II.

Authors:  S L Gibson; K R van der Meid; R S Murant; R Hilf
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

5.  Photodynamic therapy is potentiated by Co60 and intratumoral injection of hematoporphyrin derivative.

Authors:  H Kostron; M R Swartz; R L Martuza
Journal:  J Neurooncol       Date:  1988-09       Impact factor: 4.130

6.  Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution.

Authors:  M J Deurloo; W Kop; O van Tellingen; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model.

Authors:  A Obwegeser; R Jakober; H Kostron
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

8.  Selective accumulation of hematoporphyrin derivative in glioma through proton-coupled folate transporter SLC46A1.

Authors:  Tomoya Takada; Masato Tamura; Tetsuya Yamamoto; Hirofumi Matsui; Akira Matsumura
Journal:  J Clin Biochem Nutr       Date:  2013-12-20       Impact factor: 3.114

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.